News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sciele Pharma, Inc. (SCRX) and Plethora Solutions Holdings Announce Positive Results of Final Phase III Pivotal Trial for PSD502 for Premature Ejaculation


7/29/2009 9:44:44 AM

ATLANTA--(BUSINESS WIRE)--Sciele Pharma Inc.: Sciele Pharma Inc., a Shionogi Company, and Plethora Solutions Holdings PLC (“Plethora” – AIM:PLE), today announced that a second and final Phase III double-blind, placebo-controlled study of PSD502 for the treatment of premature ejaculation (‘PE’) has met all co-primary endpoints of Intra-vaginal Ejaculation Latency Time (‘IELT’), Index of Premature Ejaculation (‘IPE,’ Ejaculatory Control, Sexual Satisfaction and Distress domains).

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES